Sam Salek is Professor of Pharmacoepidemiology in the School of Life and Medical Sciences, University of Hertfordshire, UK where he leads the Public Health & Patient Safety research group. He is also the Director of the Institute for Medicine Development, Cardiff, UK, and a visiting Professor at the State of Hessen, Germany. Professor Salek is the co-founded and currently chairs the Patient Engagement Special Interest Group of the International Society of Quality of Research, and chairs the European Hematology Association Scientific Working Group for Quality of Life and Symptoms.
Professor Salek completed his undergraduate degree in Pharmacy at the University of Oklahoma in 1978. He later moved to Cardiff where he studied for his PhD, 1985–1989. Since completing his PhD, Professor Salek has held a number of academic posts on both sides of the Atlantic. His major research interests are in the development, evaluation and application of instruments to assess patient-reported outcomes and health-related quality of life (HRQoL). His other major research interests are in the areas of pharmacoeconomics/ health economics, benefit-risk assessment of medicines and pharmaceutical regulatory science.
Professor Salek has developed a few undergraduate, postgraduate diploma and MSc courses over the past 32 years which they continue to be successful. Of noteworthy: he developed and modernised the 2-year part-time Postgraduate Course in Pharmaceutical Medicine (Dip Pharm Med) and was the Course Director for 30 years; he is the founder of the MSc in International Pharmaeconomic & Health Economics in 2006 and was the Programme Director until 2015; he was the founder of the Integrated Master of Regulatory Science (an undergraduate programme) which received approval from the University of Hertfordshire Validation Board in April 2017 and due to commence in September 2018.
Professor Salek is a fellow of the Royal College of Physicians and the Royal Pharmaceutical Society of Great Britain. He is a member of five Editorial boards and has published 19 books and over 600 journal articles and abstracts. He has developed and validated 11 general and disease-specific patient-reported HRQoL measures, whilst also collaborating with the pharmaceutical industry to design HRQoL protocols for clinical trials. Increasingly, Professor Salek is shifting his emphasis towards the practical applications of HRQoL measures in clinical decision-making and policy and patient engagement in research as partners/collaborators.